吡格列酮对冠心病合并糖耐量异常患者冠脉支架内再狭窄的影响.doc

吡格列酮对冠心病合并糖耐量异常患者冠脉支架内再狭窄的影响 目录 TOC \o 1-9 \h \z \u 目录 1 正文 1 文1：吡格列酮对冠心病合并糖耐量异常患者冠脉支架内再狭窄的影响 1 1 资料和方法 2 2 结果 4 3 讨论 5 文2：吡格列酮对冠心病合并糖耐量异常患者冠脉支架内再狭窄的影响临床医学论文 6 1 资料和方法 7 2 结果 10 3 讨论 10 参考文摘引言： 12 原创性声明（模板） 13 文章致谢（模板） 13 正文 吡格列酮对冠心病合并糖耐量异常患者冠脉支架内再狭窄的影响 文1：吡格列酮对冠心病合并糖耐量异常患者冠脉支架内再狭窄的影响 Abstract: Objective To observe the effects of pioglitazone on stent restenosis in coronary heart disease patients with impaired glucose tolerance. Methods Ninetyseven percutaneous coronary intervention (PCI) patients with impaired glucose tolerance from March 2006 to March 2008 were randomly pided into pioglitazone group (n=46) receiving conventional therapy plus medication pioglitazone (15mg/day)， and control group (n=51) merely receiving conventional therapy. The groups were followed up for six months after operation. The stent restenosis rate and cardiovascular event rate were recorded. Results During the followup period， the stent restenosis rates were (±) in the pioglitazone group and (±) in the control group， with a significant difference， P; the cardiovascular events rate were significantly lower in the pioglitazone group than in the control group. Conclusion For the coronary heart disease patients with impaired glucose tolerance， taking pioglitazone after coronary stent implantation may reduce stent restenosis and the occurrence of cardiovascular events。 Key words:pioglitazone; impaired glucose tolerance; stent restenosis 目前冠状动脉内药物支架植入术已经越来越多地应用于临床，但药物支架术后支架再狭窄(instent restenosis， IR)或支架管腔丢失仍然有发生，特别是冠心病合并糖耐量异常患者。胰岛素抵抗与冠心病的发生有密切关系，Rosmarkis等［1］用Meta分析发现噻唑烷二酮类药物可减少冠状动脉介入治疗术后IR的发生;尹朝霞等［2］用相关分析表明：胰岛素抵抗与冠心病的关系非常密切，但对其防治的意义尚不清楚。本文是观察吡格列酮对冠心病合并糖耐量异常患者冠脉支架内再狭窄的影响，现将结果报道如下。 1 资料和方法 一般资料 2006年3月至2008年3月于我院行冠状动脉造影证实冠状动脉的直径狭窄程度75%接受支架植入术和胰岛素抵抗指数的患者112例。112例中属稳定型心绞痛28例和急性冠脉综合征包括不稳定型心绞痛及急性心肌梗死共84例，均可排除有支架置入术史、左室射血分数(LVEF) 方法 随访 两组患者术后均随访6个月并记录:心绞痛、心肌梗死、死亡等心血管事件及复查冠状动脉造影观察原支架内再狭窄等情况。原支架内再狭窄定义为：冠状动脉造影定量测量支架血管直径≤50%为狭窄。 支架植入术 采用Judki法经皮右侧股动脉进入，